Eiger BioPharmaceuticals Inc.

8.11-0.0200-0.25%Vol 69.20K1Y Perf -24.49%
Jun 15th, 2021 16:00 DELAYED
BID8.10 ASK8.11
Open8.16 Previous Close8.13
Pre-Market- After-Market8.11
 - -  - -%
Target Price
30.75 
Analyst Rating
Strong Buy 1.00
Potential %
279.16 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
33/-/60 
Value Ranking
★★★+ —    54.24
Insiders Value % 3/6/12 mo.
2/-31/72 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
11/-19/72 
Income Ranking
 —    -
Market Cap275.34M 
Earnings Rating
Sell
Price Range Ratio 52W %
9.12 
Earnings Date
5th Aug 2021

Today's Price Range

8.018.21

52W Range

7.5713.49

5 Year PE Ratio Range

-2.50-0.9000

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
0.87%
1 Month
-1.34%
3 Months
-18.41%
6 Months
-17.16%
1 Year
-24.49%
3 Years
-44.26%
5 Years
-59.73%
10 Years
-

TickerPriceChg.Chg.%
EIGR8.11-0.0200-0.25
AAPL129.64-0.8400-0.64
GOOG2 520.66-6.3800-0.25
MSFT258.36-1.5300-0.59
XOM64.332.26003.64
WFC45.460.31000.69
JNJ164.49-0.8800-0.53
FB336.75-0.0200-0.01
GE13.540.07000.52
JPM155.18-2.3900-1.52
Financial StrengthValueIndustryS&P 500US Markets
9.20
9.70
0.20
0.26
-4.70
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
98.60
-464.90
-446.00
-
-
RevenueValueIndustryS&P 500US Markets
3.65M
0.11
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.51-0.493.92
Q04 20200.33-0.58-275.76
Q03 2020-0.60-0.5213.33
Q02 2020-0.75-0.6020.00
Q01 2020-0.85-0.6227.06
Q04 2019-0.80-0.6913.75
Q03 2019-0.77-0.761.30
Q02 2019-0.78-0.753.85
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.52-6.12Negative
9/2021 QR-0.46-4.55Negative
12/2021 FY-1.96-30.67Negative
12/2022 FY-1.68-9.80Negative
Next Report Date5th Aug 2021
Estimated EPS Next Report-0.52
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume69.20K
Shares Outstanding33.95M
Trades Count889
Dollar Volume2.00M
Avg. Volume225.26K
Avg. Weekly Volume92.56K
Avg. Monthly Volume116.75K
Avg. Quarterly Volume178.02K

Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR) stock closed at 8.11 per share at the end of the most recent trading day (a -0.25% change compared to the prior day closing price) with a volume of 69.22K shares and market capitalization of 275.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 29 people. Eiger BioPharmaceuticals Inc. CEO is David Cory.

The one-year performance of Eiger BioPharmaceuticals Inc. stock is -24.49%, while year-to-date (YTD) performance is -34.01%. EIGR stock has a five-year performance of -59.73%. Its 52-week range is between 7.57 and 13.49, which gives EIGR stock a 52-week price range ratio of 9.12%

Eiger BioPharmaceuticals Inc. currently has a PE ratio of -9.60, a price-to-book (PB) ratio of 2.16, a price-to-sale (PS) ratio of 74.87, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -15.26%, a ROC of -14.83% and a ROE of -23.89%. The company’s profit margin is -%, its EBITDA margin is -446.00%, and its revenue ttm is $3.65 Million , which makes it $0.11 revenue per share.

Of the last four earnings reports from Eiger BioPharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.52 for the next earnings report. Eiger BioPharmaceuticals Inc.’s next earnings report date is 05th Aug 2021.

The consensus rating of Wall Street analysts for Eiger BioPharmaceuticals Inc. is Strong Buy (1), with a target price of $30.75, which is +279.16% compared to the current price. The earnings rating for Eiger BioPharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eiger BioPharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Eiger BioPharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.61, ATR14 : 0.30, CCI20 : 96.28, Chaikin Money Flow : 0.00, MACD : -0.12, Money Flow Index : 58.54, ROC : 1.25, RSI : 49.62, STOCH (14,3) : 82.46, STOCH RSI : 0.90, UO : 55.43, Williams %R : -17.54), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eiger BioPharmaceuticals Inc. in the last 12-months were: Eldon C. Mayer (Sold 1 690 shares of value $19 739 ), Evan Loh (Sold 2 000 shares of value $20 280 ), Jeffrey Glenn (Buy at a value of $229 132), Thomas J. Dietz (Buy at a value of $21 220)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Eiger BioPharmaceuticals Inc.

Eiger BioPharmaceuticals Inc is a late-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

CEO: David Cory

Telephone: +1 650 272-6138

Address: 2155 Park Boulevard, Palo Alto 94306, CA, US

Number of employees: 29

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

67%33%

Bearish Bullish

64%36%

News

Stocktwits